Page 83 - Read Online

Page 18 of 19 Serzan et al. J Cancer Metastasis Treat 2021;7:39 https://dx.doi.org/10.20517/2394-4722.2021.76

with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell
carcinoma (aRCC). J Clin Oncol 2020;38:6_suppl, 609. DOI
45. Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line
Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res 2021;27:78-86. DOI PubMed
46. Tykodi SS, Donskov F, Lee JL, Szczylik C, Malik J et al. First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal
cell carcinoma (ccRCC): updated results for KEYNOTE-427 cohort A. J Clin Oncol 2019;37:15_suppl, 4570. DOI
47. Atkins MB, Jegede O, Haas NB, et al. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients
(pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). J Clin Oncol 2020;38(15_suppl):5006. DOI
48. US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT03873402 (2021) [Last accessed on 21 May
2021].
49. Guislain A, Gadiot J, Kaiser A, et al. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in
intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol Immunother 2015;64:1241-
50. DOI PubMed
50. Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on
immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J
Transl Med 2014;12:294. DOI PubMed PMC
51. Li YL, Zhao H, Ren XB. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med
2016;13:206-14. DOI PubMed PMC
52. Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune consequences of tyrosine kinase inhibitors that synergize with cancer
immunotherapy. Cancer Cell Microenviron 2015;2:e677. DOI PubMed PMC
53. Zhang Q, Tian K, Xu J, et al. Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma. J
Immunol Res 2017;2017:6915912. DOI PubMed PMC
54. Bao Y, Wang Z, Liu B, et al. A feed-forward loop between nuclear translocation of CXCR4 and HIF-1α promotes renal cell carcinoma
metastasis. Oncogene 2019;38:881-95. DOI PubMed PMC
55. Liu XD, Hoang A, Zhou L, et al. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor
Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res 2015;3:1017-29. DOI PubMed PMC
56. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune
responses. Blood 2008;111:5610-20. DOI PubMed
57. Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or
metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer 2018;6:109. DOI PubMed PMC
58. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic
renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404-15. DOI
PubMed
59. Rini BI, Plimack ER, Stus V, et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-
cell carcinoma. N Engl J Med 2019;380:1116-27. DOI PubMed
60. Powles T, Plimack ER, Soulières D, Waddell T, Stus V et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line
treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomized, open-label, phase 3 trial.
Lancet Oncol 2020;21:1563-73. DOI PubMed
61. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med
2019;380:1103-15. DOI PubMed PMC
62. Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib
versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020;31:1030-9. DOI PubMed
63. Choueiri TK, Powles T, Burotto M, et al; CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med 2021;384:829-41. DOI PubMed
64. Regan MM, Atkins MB, Powles T, Werner L, Mantia C et al. Treatment-free survival, with and without toxicity, as a novel outcome
applied to immuno-oncology agents in advanced renal cell carcinoma. Ann Oncol 2019;30:v393-4. DOI
65. Regan M, Jegede OA, Mantia C, Powles T, Werner L et al. 713P Treatment-free survival, with and without toxicity, after immuno-
oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214. Ann Oncol
2020;31:S561. DOI
66. Cella D, Grünwald V, Escudier B, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with
nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol 2019;20:297-310. DOI
PubMed PMC
67. Leite KR, Reis ST, Junior JP, et al. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn
Pathol 2015;10:189. DOI PubMed PMC
68. Iacovelli R, Nolè F, Verri E, et al. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-
Analysis. Target Oncol 2016;11:143-8. DOI PubMed
69. Motzer RJ, Banchereau R, Hamidi H, et al. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis
Blockade. Cancer Cell 2020;38:803-17.e4. DOI PubMed
70. Kapur P, Christie A, Rajaram S, Brugarolas J. What morphology can teach us about renal cell carcinoma clonal evolution. Kidney
Cancer J 2020;18:68-75.
71. Gu YF, Cohn S, Christie A, et al. Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade. Cancer